WO2022127945A2 - Uso de péptido sintetico para la induccion de inmunidad antitumoral y antiviral - Google Patents
Uso de péptido sintetico para la induccion de inmunidad antitumoral y antiviral Download PDFInfo
- Publication number
- WO2022127945A2 WO2022127945A2 PCT/CU2021/050013 CU2021050013W WO2022127945A2 WO 2022127945 A2 WO2022127945 A2 WO 2022127945A2 CU 2021050013 W CU2021050013 W CU 2021050013W WO 2022127945 A2 WO2022127945 A2 WO 2022127945A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- cells
- peptide identified
- tumor
- induction
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 206
- 230000006698 induction Effects 0.000 title claims abstract description 42
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 28
- 230000000840 anti-viral effect Effects 0.000 title claims abstract description 23
- 230000036039 immunity Effects 0.000 title claims abstract description 22
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 113
- 238000000034 method Methods 0.000 claims abstract description 30
- 201000011510 cancer Diseases 0.000 claims abstract description 28
- 229960005486 vaccine Drugs 0.000 claims abstract description 27
- 239000003814 drug Substances 0.000 claims abstract description 25
- 229940079593 drug Drugs 0.000 claims abstract description 22
- 238000002619 cancer immunotherapy Methods 0.000 claims abstract description 18
- 230000037449 immunogenic cell death Effects 0.000 claims abstract description 16
- 230000001404 mediated effect Effects 0.000 claims abstract description 13
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- 208000036142 Viral infection Diseases 0.000 claims abstract description 5
- 230000009385 viral infection Effects 0.000 claims abstract description 5
- 238000011282 treatment Methods 0.000 claims description 88
- 210000004443 dendritic cell Anatomy 0.000 claims description 45
- 230000000694 effects Effects 0.000 claims description 42
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims description 22
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 18
- 230000004913 activation Effects 0.000 claims description 18
- 238000000338 in vitro Methods 0.000 claims description 18
- 230000001965 increasing effect Effects 0.000 claims description 17
- 210000000822 natural killer cell Anatomy 0.000 claims description 16
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 15
- 239000003112 inhibitor Substances 0.000 claims description 12
- 238000001727 in vivo Methods 0.000 claims description 11
- 230000001939 inductive effect Effects 0.000 claims description 11
- 230000028327 secretion Effects 0.000 claims description 11
- 102000004127 Cytokines Human genes 0.000 claims description 10
- 108090000695 Cytokines Proteins 0.000 claims description 10
- 230000005809 anti-tumor immunity Effects 0.000 claims description 10
- 230000001472 cytotoxic effect Effects 0.000 claims description 10
- 230000002708 enhancing effect Effects 0.000 claims description 10
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 9
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 9
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 9
- 239000000427 antigen Substances 0.000 claims description 9
- 102000036639 antigens Human genes 0.000 claims description 9
- 108091007433 antigens Proteins 0.000 claims description 9
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 9
- 230000003612 virological effect Effects 0.000 claims description 9
- 230000003308 immunostimulating effect Effects 0.000 claims description 6
- 230000001506 immunosuppresive effect Effects 0.000 claims description 6
- 230000000770 proinflammatory effect Effects 0.000 claims description 5
- 230000004069 differentiation Effects 0.000 claims description 4
- 230000028996 humoral immune response Effects 0.000 claims description 4
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 238000013459 approach Methods 0.000 abstract description 4
- 230000001024 immunotherapeutic effect Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 128
- 210000004881 tumor cell Anatomy 0.000 description 46
- 241000699670 Mus sp. Species 0.000 description 35
- 238000011156 evaluation Methods 0.000 description 27
- 241001465754 Metazoa Species 0.000 description 19
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 15
- 230000014509 gene expression Effects 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 230000004083 survival effect Effects 0.000 description 13
- 206010057249 Phagocytosis Diseases 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 230000008782 phagocytosis Effects 0.000 description 12
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 12
- 102000004082 Calreticulin Human genes 0.000 description 11
- 108090000549 Calreticulin Proteins 0.000 description 11
- 238000011765 DBA/2 mouse Methods 0.000 description 11
- 230000030833 cell death Effects 0.000 description 11
- 230000004614 tumor growth Effects 0.000 description 11
- 230000007423 decrease Effects 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- 230000006907 apoptotic process Effects 0.000 description 9
- 238000003501 co-culture Methods 0.000 description 9
- 239000012091 fetal bovine serum Substances 0.000 description 9
- 230000028993 immune response Effects 0.000 description 9
- 238000011534 incubation Methods 0.000 description 9
- 238000011081 inoculation Methods 0.000 description 9
- 210000002540 macrophage Anatomy 0.000 description 9
- 230000035800 maturation Effects 0.000 description 9
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 8
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 8
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 8
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 8
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 8
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 8
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 239000012979 RPMI medium Substances 0.000 description 7
- 230000034994 death Effects 0.000 description 7
- 231100000517 death Toxicity 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 238000001543 one-way ANOVA Methods 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 230000024932 T cell mediated immunity Effects 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 210000003690 classically activated macrophage Anatomy 0.000 description 6
- 230000009089 cytolysis Effects 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 230000002163 immunogen Effects 0.000 description 6
- 238000009169 immunotherapy Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 230000005945 translocation Effects 0.000 description 6
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 5
- 102000043139 CK2 family Human genes 0.000 description 5
- 229940122360 Casein kinase 2 inhibitor Drugs 0.000 description 5
- 238000012313 Kruskal-Wallis test Methods 0.000 description 5
- 210000004322 M2 macrophage Anatomy 0.000 description 5
- 241001529936 Murinae Species 0.000 description 5
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000004041 dendritic cell maturation Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 238000013401 experimental design Methods 0.000 description 5
- 230000008348 humoral response Effects 0.000 description 5
- 230000002601 intratumoral effect Effects 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 229940125575 vaccine candidate Drugs 0.000 description 5
- 108090000672 Annexin A5 Proteins 0.000 description 4
- 102000004121 Annexin A5 Human genes 0.000 description 4
- 241001678559 COVID-19 virus Species 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102100040247 Tumor necrosis factor Human genes 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 238000000540 analysis of variance Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000006023 anti-tumor response Effects 0.000 description 4
- 210000000612 antigen-presenting cell Anatomy 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 230000005975 antitumor immune response Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 238000001325 log-rank test Methods 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 238000000729 Fisher's exact test Methods 0.000 description 3
- 101000952113 Homo sapiens Probable ATP-dependent RNA helicase DDX5 Proteins 0.000 description 3
- 101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 102100037434 Probable ATP-dependent RNA helicase DDX5 Human genes 0.000 description 3
- 238000010162 Tukey test Methods 0.000 description 3
- 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 description 3
- 241000700618 Vaccinia virus Species 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 230000007115 recruitment Effects 0.000 description 3
- 238000011301 standard therapy Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000005751 tumor progression Effects 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 101150013553 CD40 gene Proteins 0.000 description 2
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 2
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000341655 Human papillomavirus type 16 Species 0.000 description 2
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 2
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 206010061309 Neoplasm progression Diseases 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 2
- 230000003095 anti-phagocytic effect Effects 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 229940022399 cancer vaccine Drugs 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940029030 dendritic cell vaccine Drugs 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 208000014951 hematologic disease Diseases 0.000 description 2
- 210000000548 hind-foot Anatomy 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000003614 tolerogenic effect Effects 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical group CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- 231100000582 ATP assay Toxicity 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 101150084532 CD47 gene Proteins 0.000 description 1
- 102000052052 Casein Kinase II Human genes 0.000 description 1
- 108010010919 Casein Kinase II Proteins 0.000 description 1
- 241001481710 Cerambycidae Species 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 238000011510 Elispot assay Methods 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 108010040476 FITC-annexin A5 Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 101710113864 Heat shock protein 90 Proteins 0.000 description 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- -1 IL-12p70 Proteins 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
- 206010027458 Metastases to lung Diseases 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 230000006051 NK cell activation Effects 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 108010066124 Protein S Proteins 0.000 description 1
- 102000029301 Protein S Human genes 0.000 description 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 108010087302 Viral Structural Proteins Proteins 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000006041 cell recruitment Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229940029038 dendritic cell-based cancer vaccine Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000009274 differential gene expression Effects 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000011293 immunotherapeutic strategy Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011355 in situ vaccination Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 238000011201 multiple comparisons test Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000027405 negative regulation of phosphorylation Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000009931 pascalization Methods 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000021419 recognition of apoptotic cell Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000011255 standard chemotherapy Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940124598 therapeutic candidate Drugs 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
Definitions
- the present invention relates to the field of cancer immunotherapy and antiviral therapy.
- it is based on the use of the peptide identified as SEQ ID No: 1 for the induction of antitumor and antiviral immunity mediated by immunogenic cell death, as well as the combination of said peptide with cancer immunotherapy.
- Cancer is one of the leading causes of death worldwide. The global incidence of cancer continues to rise, estimating that by 2030 new cases will exceed 21.7 million and there will be 13 million deaths from cancer per year (Tartar ⁇ F et al. Cancer Treat Rev 2016; 48:20 -24).
- the synthetic peptide identified as SEQ ID No: 1 is a therapeutic candidate in development for the treatment of cancer, the primary mechanism of action is the inhibition of phosphorylation mediated by protein kinase "CK2", thus leading to cell death. tumor by apoptosis. It has shown antitumor effect in animal models of experimental oncology (Perea SE et al. Cancer Res 2004; 64:7129-9). Recently, the antiviral effect of the peptide identified as SEQ ID No: 1 has also been observed in different viral models, in in vitro studies.
- the peptide identified as SEQ ID No: 1 interacts with the B23/Nucleofosmin protein in the tumor cell nucleolus, inhibits its phosphorylation and induces nucleolar disassembly as a prelude to apoptosis (Perera Y and cois Mol Cancer Ther 2009;8(5)). Consistent with such molecular events, the peptide identified as SEQ ID No: 1 modulates a signal of proteins linked to different cellular processes and inhibits colonization of lung metastases and tumor angiogenesis in preclinical cancer models (Farina HG et al.
- the peptide identified as SEQ ID No: 1 inhibits the phosphorylation of other CK2 substrates such as AKT and PTEN (Martins LR et al. Oncotarget 2014; 5:258-263).
- exploration of the safety and tolerability of the peptide identified as SEQ ID No: 1 in cancer patients has begun, where a trend of increased survival has been observed in patients with advanced disease, and above life expectancy (Batista-Albuerne N et al. J Med Oncol 2018; 1:4).
- chemotherapeutic drugs and radiotherapy do not have a direct stimulating effect on cellular immunity, it is now known that some of these approaches can increase it indirectly, by inducing cell death immunogenic in tumor cells.
- the number of drugs that induce immunogenic cell death has been increasing in recent years. These include: anthracyclines (doxorubicin (DOX), epirubicin, idarubicin), oxaliplatin, cyclophosphamide, bortezomib, mitoxantrone, and bleomycin (Garg AD et al. Oncoimmunology 2017; 6(12): e1386829).
- DOX doxorubicin
- epirubicin epirubicin
- idarubicin oxaliplatin
- cyclophosphamide bortezomib
- mitoxantrone and bleomycin
- necrosis was the only type of cell death considered immunogenic, producing unwanted inflammatory reactions due to the rapid release of various intracellular factors, cytokines, and other inflammatory mediators (Rock KL and Kono H. Annu Rev Pathol 2008; 3 :99-126).
- apoptosis was considered a mostly tolerogenic or immunologically silent physiological process of cell death (Matzinger P. Science 2002; 296:301-305).
- CRT calreticulin
- Erp57 Erp57
- HSP90 Hou W et al.
- immunogenic killing activates the host's immune system and increases the immune response to immunotherapy, such as the response to dendritic cell-based cancer vaccines (Vandenberk L et al. Front Immunol 2016; 6 :663).
- tumor cells undergoing immunogenic cell death induced by drugs in vitro, are capable of inducing an anticancer vaccine effect when implanted subcutaneously in immunocompetent mice (Keep O et al. Oncoimmunology. 2014, 3:9).
- dendritic cells play a role central in the recognition of apoptotic cells, and in the initiation of an effective antitumor immune response (Ma Y et al.
- the present invention solves the aforementioned problem, by providing the use of the peptide identified as SEQ ID No: 1 for the manufacture of a drug for the induction of antitumor and antiviral immunity mediated by immunogenic cell death.
- the peptide identified as SEQ ID No: 1 is a proapoptotic peptide, comprising the synthetic peptide initially called P15 fused to the cell-penetrating peptide Tat (amino acids 48-60), to facilitate the internalization within cells (Perea SE et al. Cancer res. 2004; 64: 7127-7129).
- this peptide is capable of inducing activation of antitumor immunity, by activating "eat me” type signals and reducing "don't eat me” type signals.
- the invention demonstrates that there is activation of the adaptive antitumor immune response, where there is a maturation and activation of dendritic cells and of the cellular immune response mediated by CD8+ cytotoxic T lymphocytes.
- the effect described for the peptide identified as SEQ ID No: 1 herein The invention is not observed for other inhibitors of CK2-mediated phosphorylation, such as the chemical compound CX-4945, which directly blocks the catalytic subunit of protein kinase CK2, nor is said effect observed when using the penetrating peptide Tat, which has been evaluated as a control test.
- the peptide identified as SEQ ID No: 1 is used for the manufacture of a drug for the induction of antitumor and antiviral immunity through the in vivo and in vitro activation and differentiation of dendritic cells.
- In vitro treatment is understood as the incubation of tumor cells in culture with the peptide identified as SEQ ID No: 1.
- Ex vivo treatment refers to the in vitro co-incubation of tumor cells extracted from patients who have been treated with the peptide identified as SEQ ID No: 1 in the laboratory, together with dendritic cells extracted from the same patients.
- an increase in "eat me” type signals and a decrease in "don't eat me” type signals are observed in the tumor, with the subsequent activation of the cellular immune response, both at the systemic and intratumoral.
- the peptide identified as SEQ ID No: 1 is capable of inducing immunogenic cell death of tumor cells, which administered in a vaccination scheme induce an immune response in vivo that protects against the challenge with live tumor cells and prevents tumor growth and engraftment.
- induction of antitumor immunity by use of the peptide identified as SEQ ID No: 1 comprises enhancement of NK cell cytotoxic activity or cytotoxic T cell activity at the tumor site.
- the use of the peptide identified as SEQ ID No: 1 allows to increase the activity of cytotoxic T cells through an adequate maturation and activation of dendritic cells.
- the peptide identified as SEQ ID No: 1 is capable of increase the secretion of HMGB-1 and adenosine triphosphate (ATP) by tumor cells after treatment, which act as chemoattractants for antigen-presenting cells, favoring their recruitment, maturation and activation at the tumor site.
- ATP adenosine triphosphate
- the use of the peptide identified as SEQ ID No: 1 solves said limitation, by inducing the activation of dendritic cells in vivo, without the need to extract any cells from the patient for said procedure. This effect is observed when the peptide identified as SEQ ID No: 1 is administered both intratumorally and systemically, which makes it an effective treatment for both leukemia and solid tumors, including those with difficult access.
- the induction of antitumor immunity by the use of the peptide identified as SEQ ID No: 1 comprises the reversion of the immunosuppressive tumor microenvironment to an immunostimulatory one.
- Said synthetic peptide enhances the recruitment of immune cells capable of orchestrating a specific antitumor response and decreases the presence of regulatory T cells.
- the peptide achieves the induction of antitumor and antiviral immunity by increasing the secretion of proinflammatory cytokines such as TNF-a, IL-6 and IL-12, capable of increasing the expression of MHC-I on the antigen presenting cells, and promote T cell differentiation and NK cell activation.
- the increase in pro-inflammatory cytokines is accompanied by a decrease in anti-inflammatory cytokines, such as IL-10, which limit the immune response generated and contribute to the progression of the tumor or viral infection.
- the induction of antiviral immunity comprises the enhancement of a specific humoral immune response against viral antigens, as demonstrated for the first time in the present invention.
- the ability of the peptide identified as SEQ ID No: 1 to enhance the immune response makes it an ideal candidate for use in infectious diseases, particularly during viral infections.
- the invention also comprises a method for the treatment of cancer or viral infections characterized in that a therapeutically effective amount of a drug is administered to an individual in need for the induction of antitumor and antiviral immunity, mediated by immunogenic cell death where the medicament comprises the peptide identified as SEQ ID No: 1.
- the method of the present invention makes it possible to decrease “don't eat me” type signals such as CD47, which, together with the increase in “eat me” signals, favor the phagocytosis of tumor cells by dendritic cells and by M1 macrophages, these the latter related to antiangiogenic functions that inhibit tumor progression.
- This effect eliminates the need to use CD47 inhibitors to enhance the antitumor effect of certain drugs and thus reduce the number of compounds needed to achieve an effective antitumor response. Therefore, in one embodiment of the method of the invention, the induction of antitumor and antiviral immunity comprises the in vivo and in vitro activation and differentiation of dendritic cells.
- the use of the peptide identified as SEQ ID No: 1 increases "eat me” type signals such as CRT. This makes it possible to increase the ability of antigen-presenting cells to capture apoptotic bodies of tumor cells.
- the increase in "eat me” type signals induced by the peptide identified as SEQ ID No: 1 also influences the increased susceptibility of tumor cells to NK cell attack, which favors the diversification of the induced response and increases the effectiveness. Therefore, in a materialization of the method of the invention, the induction of antitumor immunity comprises the enhancement of the cytotoxic activity of NK cells or the activity of cytotoxic T cells at the tumor site, as well as the reversion of the immunosuppressive tumor microenvironment to immunostimulator. , and increased secretion of pro-inflammatory cytokines. In another embodiment of the method of the invention, the induction of antiviral immunity comprises the enhancement of a specific humoral immune response against viral antigens.
- the drug comprising the peptide identified as SEQ ID No: 1 enhances the effect of a vaccine used in cancer immunotherapy.
- the drug comprising the peptide identified as SEQ ID No: 1 and the vaccine used in the immunotherapy of cancer can be administered sequentially or simultaneously in the course of the same treatment.
- the vaccine used in cancer immunotherapy is a vaccine based on dendritic cells, cytotoxic T cells or lymphocytes that infiltrate the tumor.
- the use of the peptide identified as SEQ ID No: 1, CK2 inhibitor, as an adjuvant to enhance the cellular immune response of antitumor vaccines is described for the first time.
- the peptide can be administered intratumorally or systemically prior to vaccination, which allows it to be used for both leukemia and solid tumors. It is necessary to highlight that this adjuvant capacity was only observed for the peptide identified as SEQ ID No: 1, and not for another CK2-mediated phosphorylation inhibitor, such as compound CX-4945.
- Another object of the present invention is a pharmaceutical combination comprising the peptide identified as SEQ ID No: 1 and a vaccine for cancer immunotherapy.
- the vaccine used in cancer immunotherapy is a vaccine based on dendritic cells, cytotoxic T cells or tumor-infiltrating lymphocytes (TIL).
- cytotoxic T lymphocytes The ability to increase tumor infiltration of cytotoxic T lymphocytes, and decrease the presence of regulatory cells, makes the peptide identified as SEQ ID No: 1 a suitable compound to enhance the effect of CTL-based vaccines (Cytotoxic T Lymphocyte) and TIL, and thus achieve a better immunotherapeutic approach, more effective against cancer.
- the drug comprising the peptide identified as SEQ ID No: 1 potentiates the effect of an inhibitor of the PDL1 immune checkpoint used in cancer immunotherapy.
- the peptide identified as SEQ ID No: 1 and the PDL1 immune checkpoint inhibitor are administered sequentially or simultaneously in the course of the same treatment.
- the PDL1 immune checkpoint inhibitor is an anti-PDL1 monoclonal antibody.
- the invention discloses a pharmaceutical combination comprising the peptide identified as SEQ ID No: 1 and an inhibitor of the PDL1 immune checkpoint used in cancer immunotherapy.
- the PDL1 immune checkpoint inhibitor is an anti-PDL1 monoclonal antibody.
- PDL1 immune checkpoint inhibitors For example, in patients with non-small cell lung cancer lacking actionable mutations, the most effective therapy is PDL1 immune checkpoint inhibitors. However, its efficacy depends on the level of expression of this molecule in the tumor.
- the use of the peptide identified as SEQ ID No: 1 in combination with a PDL1 inhibitor solves this problem, by increasing the expression of PDL1, and therefore increasing the clinical efficacy of the PDL1 inhibitor. This combination offers a novel therapeutic strategy for the treatment of cancer.
- Figure 1 Evaluation of the induction of cell death in the L1210 (A) and 3LL (B) cell lines by the peptide identified as SEQ ID No: 1.
- the bar graphs indicate the frequency of dead cells (Annexin V+/7AAD+) and dying cells (Annexin V+/7AAD-) after treatment with the peptide identified as SEQ ID No: 1.
- Positive error bars indicate standard deviations from the mean of replicates.
- FIG. 1 Evaluation of the induction of apoptosis ex vivo by the peptide identified as SEQ ID No: 1 in cells from patients with malignant blood diseases.
- the figure shows the percentage of Annexin V/IP+ cells from 10 patients with malignant blood diseases after ex vivo treatment with the peptide identified as SEQ ID No: 1 for 48 hours.
- FIG. 3 Flow cytometric analysis of CRT translocation to the membrane of L1210 cells after treatment with the peptide identified as SEQ ID No: 1.
- the figure shows the percentage of CRT+ cells after treatment with the peptide identified as SEQ ID No: 1 and CX4945.
- the graph is plotted as the mean ⁇ standard deviation of six replicates from three independent experiments.
- the asterisk indicates statistically significant differences in the percentage of CRT+ cells with respect to cells without treatment and those treated with CX4945 (Fisher's exact test, p ⁇ 0.05).
- Figure 4 Flow cytometric analysis of the translocation of Erp57 to the membrane of L1210 cells after treatment with the peptide identified as SEQ ID No: 1.
- the figure shows the percentage of Erp57+ cells after treatment with the peptide identified as SEQ ID No: 1 and CX4945.
- the graph is plotted as the mean ⁇ standard deviation of six replicates from three independent experiments.
- the asterisk indicates statistically significant differences in the percentage of Erp57+ cells with respect to cells without treatment and those treated with CX4945 (Fisher's exact test, p ⁇ 0.05).
- FIG. 1 Microarray analysis (A) and quantitative PCR (qPCR) (B) of CD47 expression in HL60 and OCI-AML3 cells after treatment with the peptide identified as SEQ ID No: 1.
- the bars represent the factor change of the CD47 gene, relative to the untreated cell control, normalized with the three reference genes GAPDH, DDX5 and ABL1.
- the data was processed using the REST 2009 v2.0.13 program.
- the asterisk represents statistically significant differences.
- FIG. 6 Evaluation of the secretion of HMGB-1 in the culture supernatant of various tumor lines treated with the peptide identified as SEQ ID No: 1.
- the graphs represent the levels of HMGB-1 determined by ELISA from the culture supernatant of the different tumor lines. The bars represent the mean ⁇ standard deviation of three independent replicates. Statistical significance was determined using the Kruskal-Wallis test and Dunn's multiple comparisons. Different letters indicate statistically significant differences: p ⁇ 0.05.
- FIG. 7 Detection of HMGB-1 in the serum of patients with acute myeloid leukemia treated with the peptide identified as SEQ ID No: 1.
- the graph represents the levels of HMGB-1 determined by ELISA from the serum of five patients treated with the peptide. Samples were taken at 0, 3 and 6 weeks after treatment.
- Figure 8 Detection of ATP in the culture supernatant of various tumor lines treated with the peptide identified as SEQ ID No: 1.
- the graphs represent the levels of ATP given by the relative light units (RLU) detected in each condition.
- the bars represent the mean ⁇ standard deviation of three independent replicates. Statistical significance was determined by the Kruskal-Wallis test and Dunn's multiple comparisons. Different letters indicate statistically significant differences: p ⁇ 0.05.
- Figure 9 Expression of HSP70 in the cell membrane of various tumor lines after treatment with the peptide identified as SEQ ID No: 1.
- the graphs represent the percentage of HSP70+ cells.
- the bars represent the mean ⁇ standard deviation of three independent replicates. Statistical differences were determined by one-tailed ANOVA, *p ⁇ 0.05, **p ⁇ 0.01.
- FIG. 10 Phagocytosis study of the L1210 and 3LL cell lines by dendritic cells after treatment with the peptide identified as SEQ ID No: 1.
- the graph shows the percentage of CD11 c+/CFSE+ cells. Error bars indicate the standard deviation of the mean of six replicates from three independent experiments. Different letters indicate statistically significant differences (Fisher's exact test; p ⁇ 0.05).
- FIG. 11 Expression of dendritic cell maturation markers after co-culture with L1210 and 3LL cells treated with the peptide identified as SEQ ID No: 1. Bar graphs show expression of dendritic cell maturation markers after co-culture. -culture with tumor cells L1210 (A) and 3LL (B).
- FIG. 12 In vitro activation of OT-I CD8+ cells by dendritic cells.
- the graph shows the concentration of IFN-y detected by ELISA in the supernatant of the co-culture of dendritic cells and tumor cells, previously treated with the peptide identified as SEQ ID No: 1, CX4945, Tat or DOX, 48 hours later. Error bars indicate standard deviations from the mean of six replicates from three independent experiments. Different letters indicate statistically significant differences in IFN-y concentration (Kruskal-Wallis test and Dunn's multiple comparisons, p ⁇ 0.05).
- SEQ1 SEQ ID No: 1. On the x-axis the concentration of the OVA class I peptide of SIINFELK sequence is represented.
- FIG. 13 Quantification of the levels of IL-12p70 (A), TNF-a (B), IL-6 (C) and IL-10 (D) in peripheral blood serum of DBA/2 mice challenged with L1210 cells, seven days after treatment with the peptide identified as SEQ ID No: 1.
- the graphs show the cytokine levels of individual mice (mean ⁇ standard deviation). Different letters indicate statistically significant differences (Kruskal-Wallis test and Dunn's multiple comparisons, p ⁇ 0.01).
- Figure 14 Study of different cell populations infiltrated in the tumor seven days after treatment of DBA/2 mice with the peptide identified as SEQ ID No: 1.
- the figure shows the percentage of CD8+ T cells (A), CD4+ T cells ( B), CD11 c/CD86/MHC-ll+ dendritic cells (C) and Foxp3+ T cells (D) infiltrated in tumors of DBA/2 mice treated with the peptide identified as SEQ ID No: 1, CX4945, DOX or Tat.
- Statistical differences were determined by one-tailed ANOVA, p ⁇ 0.05.
- Figure 15 Evaluation of the in vivo immunogenicity of L1210 cells treated with the peptide identified as SEQ ID No: 1 in DBA/2 mice.
- the graphs corresponding to the tumor growth curve (mean ⁇ standard deviation) (A) and survival (Kaplan-Meier curve) (B) are shown. Different letters indicate statistically significant differences (p ⁇ 0.05) in the comparisons made between the groups, using a one-way ANOVA test and Tukey's comparison test for tumor volume, and the Log-rank test for tumor volume. survival analysis.
- FIG. 16 Evaluation of the cellular immune response of IFN- ⁇ secretion against the ovalbumin protein OVA (A) and the MHC Class I restricted OVA peptide SIINFELK (B) in C57/BL6 mice after inoculation of 3LL- OVA. Results are shown as the mean number of spots per million cells for each group ⁇ standard deviation. Different letters indicate statistically significant differences in the number of points per million cells (Kruskal-Wallis test and Dunn's multiple comparisons, p ⁇ 0.05).
- FIG. 17 NK cell cytotoxic activity on K562 cells after treatment with the peptide identified as SEQ ID No: 1.
- the graph shows the mean ⁇ standard deviation of three independent replicates.
- Asterisk (*) indicates statistically significant differences in % specific lysis from baseline control (one-way ANOVA, Tukey's multiple comparison test, p ⁇ 0.05).
- SEQ1 SEQ ID No: 1
- FIG. 18 Evaluation of the effect of the peptide identified as SEQ ID No: 1 on the phagocytic capacity of the M1 and M2 macrophage subtypes in vitro.
- OCI-AML3 (A) and HL-60 (B) cells were treated with the peptide identified as SEQ ID No: 1, CX4945 or Tat.
- the graph shows the mean ⁇ standard deviation of three independent experiments.
- the asterisk (*) indicates statistically significant differences in the percentage of CFSE+ cells in each macrophage subtype evaluated, with respect to cells without treatment (one-way ANOVA, Tukey's multiple comparisons test, p ⁇ 0.05).
- FIG. 19 Evaluation of the antitumor effect of the combination of the peptide identified as SEQ ID No: 1 and the vaccine candidate CIGB550-E7+VSSP.
- the figure shows the graphs corresponding to the tumor growth curve (mean ⁇ standard deviation) (A) and survival (Kaplan-Meier curve) (B). Different letters indicate statistically significant differences (p ⁇ 0.05) in the comparisons made between the groups using a one-way ANOVA test and Tukey's comparison test for tumor volume and Log-rank test for analysis in the survival.
- FIG 20 Evaluation of the humoral response against the OVA protein. Results are shown as the reciprocal of the mean antibody titer against OVA protein, determined by ELISA, on days 21 (A) and 42 (B) of the immunization schedule. Error bars indicate the standard deviation of the mean titers in each group. Different letters indicate statistically significant differences in antibody titers (ANOVA, Tukey's multiple comparison test, p ⁇ 0.01).
- FIG. 21 Evaluation of the humoral response against the proteins Core.120, E1.340 and E2.680. Results are shown as the reciprocal of the mean antibody titer against Core.120, E1.340, and E2.680 proteins determined by ELISA six days after challenge with a recombinant vaccinia virus expressing vaccinia virus structural proteins. hepatitis C (HCV). The error bars indicate the standard deviation of the mean of the antibody titers against each protein, “a”: denotes statistically significant differences with respect to the control group in terms of antibody titers (ANOVA, Tukey's multiple comparison test, p ⁇ 0.01).
- FIG 22 Evaluation of the humoral response against the nucleocapsid (NP) (A) and the protein S receptor binding domain (RBD) (B) of the SARS-CoV-2 virus.
- the graphs show the levels of IgG antibodies in the samples of patients treated with the peptide identified as SEQ ID No: 1 plus the standard therapy and the control group treated only with the standard treatment. Significance levels p ⁇ 0.05 (Wilcoxon test).
- DO/CO Optical density of the sample between the cut-off value of the assay.
- Figure 23 Evaluation of the ability of the peptide identified as SEQ ID No: 1 to enhance the effect of a treatment based on dendritic cells.
- the figure shows the graphs corresponding to the tumor growth curve (mean ⁇ standard deviation) (A) and survival (Kaplan-Meier curve) (B). Different letters indicate statistically significant differences (p ⁇ 0.05) in the comparisons made between the groups, using a one-way ANOVA test and Tukey's comparison test for tumor volume and Log-rank test for analysis. in survival.
- Figure 24 Evaluation of the ability of the peptide identified as SEQ ID No: 1 to enhance the effect of an antitumor treatment based on TIL.
- the figure shows the graphs corresponding to the tumor growth curve (mean standard deviation) (A) and survival (Kaplan-Meier curve) (B). Different letters indicate statistically significant differences (p ⁇ 0.05) in the comparisons made between the groups using a one-way ANOVA test and Tukey's comparison test for tumor volume and Log-rank test for analysis in the survival.
- Figure 25 Evaluation of the ability of the peptide identified as SEQ ID No: 1 to improve the antitumor efficacy of anti-PDL1 therapy.
- the figure shows the graph corresponding to the tumor growth curve (mean ⁇ standard deviation). Different letters indicate statistically significant differences (p ⁇ 0.05) in comparisons made between groups using a one-way ANOVA test and Tukey's comparison test for tumor volume.
- L1210 murine lymphocytic leukemia cells were treated with 10 pM of the peptide identified as SEQ ID No: 1 for 20 minutes at 4 S C and 37°C. After that time, the cells were marked with Annexin V-FITC, which detects phosphatidyl serine residues in the membrane of apoplectic cells, and 7AAD, which only penetrates dead cells. Finally, the samples were analyzed by flow cytometry.
- Example 2 Induction of CRT and Erp57 translocation by the peptide identified as SEQ ID No: 1.
- the exposure of CRT on the membrane of tumor cells constitutes a phagocytic signal (“eat me” type signal) for dendritic cells, which also occurs accompanied by Erp57.
- a phagocytic signal (“eat me” type signal) for dendritic cells, which also occurs accompanied by Erp57.
- Example 3 Decrease in the CD47 "dont eat me” signal in tumor cells treated with the peptide identified as SEQ ID No: 1.
- the experimental design consisted of 8 experimental groups in both lines per treatment with 40 pM of the peptide identified as SEQ ID No: 1, for 30 minutes and 3 hours, with cell controls at each time. Three experimental replicates per group were used, in plates with 12 wells, for a total of 24 independent samples, as shown in Table 1.
- RNA samples were resuspended in nuclease-free water and stored at -70 S C until differential gene expression analysis by microarray. The results were validated by qPCR.
- the oligonucleotides used are shown in Table 2. GAPDH, DDX5 and ABL1 were used as reference genes. The reactions were carried out in the LightCycler®480ll equipment (Roche, Germany) in 96-well plates in SYBR Green Probe II mode.
- the Change Factor (CF) of each gene of interest was determined with respect to the untreated cell control, normalized with the three reference genes GAPDH, DDX5 and ABL1. As shown in Figure 5, treatment with the peptide identified as SEQ ID No: 1 for 3 hours induced a significant decrease in CD47 messenger RNA (mRNA) levels in both cell lines tested. This was observed both by microarray ( Figure 5A) and by qPCR ( Figure 5B). These results indicate that the peptide identified as SEQ ID No: 1 modulates the levels of "don't eat me" signals such as CD47.
- mRNA messenger RNA
- Example 4 Induction of danger signals by the peptide identified as SEQ ID No: 1.
- HSP70 and HMGB-1 For the in vitro detection of ATP, HSP70 and HMGB-1, 6x10 4 cells were cultured in 24-well plates and treated with: 40 pM of the peptide identified as SEQ ID No: 1 and Tat for 5 and 24 hours, and 5 pM of CX4945 for 24 hours. Cells treated with 5 pM DOX for 24 hours constituted the positive control of the assay. Cells without treatments and serum from patients taken at time zero constituted negative controls. ATP secretion was determined using the ENLITEN ATP assay (Promega), HSP70 by labeling with an anti-HSP70 antibody (clone C92F3A-5, Enzo Life Sciences) and HMGB-1 was detected by ELISA (IBL International), following the recommendations from manufacturers.
- ENLITEN ATP assay Promega
- HSP70 by labeling with an anti-HSP70 antibody (clone C92F3A-5, Enzo Life Sciences)
- HMGB-1 was detected by ELISA (IBL
- Treatment with the peptide identified as SEQ ID No: 1 for 5 and 24 hours induced the secretion of HMGB-1 into the culture medium.
- the levels detected were statistically higher than those found in cells without treatments or in those treated with the Tat peptide or the CK2 inhibitor called CX4945 ( Figure 6).
- the levels of HMGB-1 secreted into the medium by cells treated with the peptide identified as SEQ ID No: 1 were significantly higher than those of cells treated with DOX.
- an increase in the levels of HMGB-1 was also observed (FIG. 7). This was observed in 4 of 5 patients evaluated, mainly at the sixth week of treatment.
- ATP levels also increased significantly in the culture medium of tumor cells, after treatment with the peptide identified as SEQ ID No: 1 for 5 and 24 hours, compared to untreated cells and those treated with CX4945 ( Figure 8). The levels were even higher than those detected after treatment with the immunogenic cell death inducer, DOX. Similar results were obtained when evaluating HSP70. Treatment with the peptide identified as SEQ ID No: 1 for 5 and 24 hours induced a significant increase in the percentage of positive HSP70 cells, compared to the rest of the conditions evaluated ( Figure 9). These results demonstrate that the peptide identified as SEQ ID No: 1, unlike CX4945 and Tat, causes the induction of danger signals involved in the recruitment and activation of immune cells.
- Example 5 Phagocytosis, maturation and in vitro activation of dendritic cells by tumor cells treated with the peptide identified SEQ ID No: 1.
- L1210 and 3LL cells were taken and treated in T25 flasks with 40 pM and 130 pM, respectively. , of the peptide identified as SEQ ID No: 1, for 3 hours.
- the tumor cells were previously labeled with 1 pM CFSE (Carboxyfluorescein succinimidyl este). After treatment, tumor cells were washed and seeded in 96-well U-bottom plates, in a 1:2 ratio with respect to dendritic cells, for 48 hours.
- CFSE Carboxyfluorescein succinimidyl este
- Dendritic cells were differentiated using FLT3, from bone marrow precursors of DBA/2 mice, for co-culture with L1210 cells, and C57/BL6 for the experiment with 3LL cells.
- the co-culture was labeled with anti-CD11c antibody, in the case of phagocytosis experiments, or with anti-CD11c, anti-CD86, anti-MHCII and anti-CD40 antibodies for dendritic cell maturation experiments. .
- Cells without treatment constituted the negative control of the experiment. DOX-treated cells were used as positive control.
- the effect of Tat and the CK2 inhibitor called CX4945 in stimulating phagocytosis was also evaluated.
- dendritic cells matured with 3LL cells treated with the peptide identified as SEQ ID No: 1, to activate CD8+ T cells in vitro was evaluated.
- dendritic cells previously co-incubated with tumor cells, under the conditions described above, were washed and loaded with the OVA peptide SIINFELK, restricted for MHC class I, at different concentrations (0, 10, 30 and 100 pg/mL) for three hours. After that time, they were washed again and co-incubated with RagOT-1 cells in a 1:1 ratio for 48 hours. IFN- ⁇ production was quantified by ELISA after culture time.
- Dendritic cells matured with 3LL cells treated with the peptide identified as SEQ ID No: 1 and DOX, were able to activate CD8+ OT-I cells given an increase in IFN-y production, which was significantly higher than that detected in the negative control and with cells treated with CX4945 and Tat (FIG. 12). These results demonstrate that treatment with the peptide identified as SEQ ID No: 1 induces the expression of molecules that stimulate phagocytosis and maturation of dendritic cells, as well as an increase in their ability to activate CD8+ T cells, which could indicate the start of an induction of antitumor response.
- Example 6 Evaluation of the effect of the peptide identified as SEQ ID No: 1 on the tumor microenvironment in DBA/2 mice.
- mice Female DBA/2 mice, 6-8 weeks old, and between 17-19 grams were inoculated with 0.5x10 6 L1210 cells, via subcutaneously, in the right hind leg (inguinal inoculation). Seven days after tumor challenge, 42 animals with palpable and non-measurable tumors were selected and arbitrarily assigned to six groups of seven animals each. The animals received the treatments as shown in Table 3.
- the treatment with the peptide identified as SEQ ID No: 1 (at 20 mg/kg) was administered intratumorally and intravenously, in a volume of 50 pl and 100 pl, respectively, with a daily inoculation for five days.
- DOX (10 mM) and Tat (20 mg/kg) were administered intratumorally, in a final volume of 50 pL, one daily inoculation for five days.
- Compound CX4945 (75 mg/kg) was administered in 25 mM NaH 2 PO 4 buffer twice a day orally for five days.
- Seven days after the end of the treatment the mice were sacrificed to obtain the tumors (day 18 of the procedure). Before sacrificing the mice, blood samples were obtained for the determination of cytokines (IL-6, IL-10, IL-12p70, TNF-a) by ELISA.
- cytokines IL-6, IL-10, IL-12p70, TNF-a
- Tumors were cut into small pieces and transferred to gentleMACS tubes containing RPMI medium, supplemented with an enzyme cocktail from the Tumor Dissociation kit (Miltenyi Biotech, Germany). Tumor dissociation was performed using the gentleMACSTM Dissociator and a tumor dissociation kit (Miltenyi Biotech, Germany). The digested suspension was filtered, centrifuged and labeled with specific antibodies against CD8, CD4, Foxp3, CD11 c, CD86 and CD40.
- R tumor challenge
- I intratumoral immunization
- IV intravenous
- O oral administration twice a day
- ET sacrifice of the mice and tumor extraction.
- treatment with the peptide identified as SEQ ID No: 1 by the two routes of administration evaluated, caused a significant increase in the levels of CD8+ and CD4+ T cells infiltrated in the tumor, as well as the in situ maturation of dendritic cells, due to an increase in the maturation markers CD86 and MHC-II. Additionally, a significant decrease was observed in the levels of intratumoral Foxp3+ T cells after treatment with the peptide identified as SEQ ID No: 1 and DOX, obtaining a greater reduction after the application of the peptide. These changes in the levels of these cells were not observed when the mice were treated with Tat or CX4945 (FIG. 14). These results indicate that treatment with the peptide identified as SEQ ID No: 1 is capable of reverting the immunosuppressive environment of the tumor to an immunostimulatory one, with a marked increase in dendritic cell maturation and recruitment of effector cells.
- Example 7 Evaluation of the vaccinal effect of the inoculation of tumor cells treated with the peptide identified as SEQ ID No: 1 in DBA/2 mice.
- a positive control cells treated with 15 pM DOX for 24 hours were used for vaccination.
- Example 8 Evaluation of the effect of tumor cells treated with the peptide identified as SEQ ID No: 1 to generate a cellular immune response in C57/BL6 mice.
- the IFN- ⁇ secretion response was evaluated by ELISPOT (Enzyme Linked Immunopot Assay), following the procedure described below.
- 96-well microplates with nitrocellulose membranes (Millipore, Bedford, MA, USA) were used, which were coated with 100 pL/well of the murine anti-IFN-y monoclonal antibody (BD Biosciences, Canada), at a concentration of 5 pg/mL in PBS, for 16 hours at 4°C. After three washes with PBS, the plates were blocked with RPMI medium supplemented with 10% FBS, for 1 hour at 37°C, in a humid atmosphere with 5% CO2.
- the plates were incubated for 48 hours at 37°C, in a humid atmosphere of 5% CO 2 . After incubation, a standard ELISPOT assay (Vázquez-Blomquist D. et al. (2002) Viral Immunol. 5(2):337-356) was performed. The counting of the points was carried out using a counter automatic (Immunospot Analyzer, Cellular Technology Ltd., Shaker Heights, OH, USA). Cells incubated with RPMI medium containing 10% FBS were taken as negative controls.
- results were considered positive when the number of points was at least 3 times higher than the average number of points in the negative control group and there were at least 3 specific points (value obtained after subtracting the number of points of an individual animal in a stimulation condition minus the number of points of the same in the non-stimulation condition) for every 10 6 cells.
- Example 9 Evaluation of the increased susceptibility of tumor cells to the action of NK cells after treatment with the peptide identified as SEQ ID No: 1.
- NK cells were isolated from peripheral blood mononuclear cells (PBMC) of healthy donors, by negative selection, using magnetic beads (Miltenyi Biotec). CD56+CD3- NK cells were obtained with more than 96% purity.
- the peptide identified as SEQ ID No: 1 was added to the time to co-culture, at a concentration of: 12.5 pM; 25 pM and 50 pM. After 4 hours of incubation, the supernatant was collected for the measurement of Cr 51 release, using a scintillation counter. The percentage of specific lysis was calculated as follows:
- White cells alone were used as a control for spontaneous lysis.
- White cells with the peptide identified as SEQ ID No: 1 constitute the peptide toxicity control.
- the results obtained indicate that the peptide identified as SEQ ID No: 1 is capable of sensitizing the tumor cell to the direct action of NK cells, which helps to generate a diverse and effective immune response.
- Example 10 Evaluation of the sensitization of tumor cells to the cytotoxic effect of macrophages by the peptide identified as SEQ ID No: 1.
- the cells were washed and co-cultured with each type of macrophages M1 and M2, at a 1:1 ratio for 3 hours.
- the different types of macrophages were prepared from PBMC from healthy donors, obtained by FicollTM gradient Monocytes were purified by positive selection, using CD14 beads with an MS column (Miltenyi Biotech, Germany), obtaining a 96% purity of these cells. Monocytes were seeded at 0.25x10 6 cells/ml/well, in 12-well plates and induced with 100 ng/mL of GM-CSF, for 7 days, and with 50 ng/mL of IFN-y for the last ones. 24 hours, to obtain M1 macrophages.
- M2 macrophages For M2 macrophages, they were induced with 50 ng/mL of M-CSF for 7 days, and with 100 ng/mL of IL-10 in the last 24 hours. After the incubation time, the supernatant was collected and the cells were labeled with anti-CD33 antibodies (for the determination of the population corresponding to macrophages), anti-CD86 (to determine the M1 population) and anti-CD163 (for the population M2).
- Example 11 Evaluation of the antitumor effect of the combination of the peptide identified as SEQ ID No: 1 and the vaccine candidate CIGB550-E7+VSSPs in the therapeutic scenario of the TC-1 model.
- CIGB550 -E7+VSSPs a CTL vaccine candidate
- This candidate is composed of the recombinant fusion protein CIGB550-E7, based on the fusion of an E7 mutein of human papillomavirus type 16 (HPV-16) to a cell-penetrating peptide with immunostimulatory properties (CIGB550), formulated with the synthetic NAcGM3/VSSP adjuvant.
- mice Female C57BL/6 mice, 6-8 weeks old, weighing between 17-19 grams, were inoculated with 5x10 4 TC-1 cells, subcutaneous in the right hind leg (inguinal inoculation). Seven days after tumor challenge, 48 mice with palpable and non-measurable tumors were selected and arbitrarily assigned to six groups of 10 animals each. The animals received the different treatments as shown in Table 4.
- the treatment with the peptide identified as SEQ ID No: 1 (at 40 mg/kg) was administered intratumorally and intravenously, in a final volume of 50 pL and 100 pL, respectively.
- Compound CX4945 (at 75 mg/kg) was administered orally in 25 mM NaH 2 PO 4 buffer twice daily.
- the administration of the vaccine candidate CIGB550-E7+VSSPs was carried out subcutaneously, in the right flank of the mouse and in volumes of 0.2 mL. Tumor kinetics in the different groups was followed by tumor volume, which was determined and calculated as described in Example 7.
- Peptide Peptide SEQ ID No: 1, R: tumor challenge, I: intratumoral immunization, IV: intravenous immunization, SC: subcutaneous immunization, O: twice daily oral administration.
- Example 12 Evaluation of the ability of the peptide identified as SEQ ID No: 1 to enhance an immune response of B cells.
- mice 30 female BALB/c mice, 8 weeks old and 18- 20 grams of body weight were divided into three groups of 10 mice each.
- the first group was immunized with 10 pg of OVA protein adjuvanted in aluminum phosphate.
- the second group received 10 pg of the OVA protein and 100 pg of the peptide identified as SEQ ID No: 1.
- the third group constituted the control of the study and was inoculated only with aluminum phosphate.
- the administrations were carried out on days 0, 14 and 28, subcutaneously, in a final volume of 100 pL. On days 21 and 42, blood samples were taken to evaluate the induction of the IgG response against OVA.
- mice 14 female BALB/c mice, 8 weeks old and weighing 18-20 grams, were challenged with a recombinant vaccinia virus that expresses the structural proteins of HCV (Alvarez-Lajonchere et al. Biotecnolog ⁇ atianda 2007; 24(3)). The virus was inoculated at a dose of 10 6 plaque-forming units (pfu) in 200 pL of PBS, intraperitoneally. The next day the mice were divided into two groups of seven mice each group.
- pfu plaque-forming units
- mice of the first group were administered 3 mg/kg of the peptide identified as SEQ ID No: 1 and PBS was administered to the second group, both intraperitoneally on days: 1, 2, 3 and 4 of the study.
- a total blood extraction was performed to evaluate the humoral response against the structural proteins of HCV.
- Example 13 Evaluation of the ability of the peptide identified as SEQ ID No: 1 to enhance the effect of dendritic cell vaccines.
- Dendritic cells were obtained with more than 90% purity, determined by the expression of CD11 c by flow cytometry. Purified cells were loaded with OVA protein (Sigma-Aldhch) (100 pg/mL) in IMDM medium, supplemented with 10% FBS, for 16 hours at 37°C. Non-adherent, OVA-loaded dendritic cells (DC+OVA) were harvested for inoculation into the animals. Dendritic cells alone were used as a study control.
- OVA protein Sigma-Aldhch
- DC+OVA Non-adherent, OVA-loaded dendritic cells
- Compound CX4945 (75 mg/kg) was administered in 25 mM NaH 2 PO 4 buffer twice daily, orally.
- the administration of 5x10 5 dendritic cells loaded or unloaded with OVA was performed intratumorally, in a final volume of 50 pL.
- the tumor kinetics in the different groups was followed by the tumor volume, which was determined and calculated as described in Example 7.
- the survival of the animals was recorded until the tumor volume reached 4000 mm 3 , at which time the Animals were sacrificed by cervical dislocation. Throughout the experimentation, the mice were kept in a pathogen-free environment and the procedures were carried out in accordance with the animal treatment standards of the center's Bioteho. Table 5. Summary of the experimental design.
- R tumor challenge
- I intratumoral immunization
- O oral administration, twice a day.
- the treatment based on the combination of the peptide of SEQ ID No: 1 with a dendritic cell vaccine allows to control tumor growth in C57/BL6 mice.
- the tumor volume in that group was significantly lower than that of the rest of the study groups ( Figure 23A).
- Statistically significant differences were also observed regarding the survival of the animals treated with the combination, with respect to the rest of the groups ( Figure 23B).
- Example 14 Evaluation of the ability of the peptide identified as SEQ ID No: 1 to enhance the effect of an antitumor treatment based on tumor-infiltrating lymphocytes.
- TIL tumor infiltration of CD8+ T cells.
- SEQ ID No: 1 it was decided to evaluate whether the peptide identified as SEQ ID No: 1 is capable of enhancing the effect of the application of TIL for the treatment of cancer in a murine model. For this, female DBA/2 mice, 6-8 weeks old, and 17-19 grams of body weight were taken, which were inoculated with 5x10 4 L1210 cells, subcutaneously in the right hind leg (inguinal inoculation).
- mice with palpable tumors were selected and non-medial, which were arbitrarily assigned to six groups of seven animals each.
- the animals received the different treatments as shown in Table 3, Example 6.
- Seven days after the end of the treatment the mice were sacrificed to obtain the tumors.
- the tumors were cut into small pieces with an approximate size of 1-3 mm 3 and seeded in 24-well plates, in RPMI medium supplemented with 10% FBS and 2000 IU/mL of murine recombinant IL-2.
- the culture was expanded to 12-well plates.
- the TILs of each fragment of the same tumor were united and counted.
- mice 5x10 6 TIL were inoculated, intravenously, and the next day those same mice were challenged with 5x10 4 L1210 cells. Tumor kinetics in the different groups was followed by tumor volume, which was determined and calculated as described in Example 7.
- TIL from mice treated with the peptide identified as SEQ ID No: 1 both intratumorally and systemically, controlled tumor growth after challenge. Tumor volume in these groups was significantly lower than the rest of the study groups (FIG. 24A). Statistically significant differences were also observed regarding the survival of the animals treated with TIL from mice treated with the peptide identified as SEQ ID No: 1, with respect to those from mice treated with DOX, CX4945 or Tat ( Figure 24B). . These results demonstrate that the peptide identified as SEQ ID No: 1 is capable of enhancing the effect of TIL-based vaccines.
- Example 15 Evaluation of the capacity of the peptide identified as SEQ ID No: 1 to modulate the levels of the PDL1 immune control point.
- Immune checkpoints are currently an important target in cancer immunotherapy due to their immunosuppressive role during the course of this disease. Taking this into account, the effect of the peptide identified as SEQ ID No: 1 on the modulation of PDL1 levels in two non-small cell lung cancer cell lines: A549 and H460 was evaluated. For this, 5x10 4 cells were seeded in 24-well plates. After attachment, the cells were treated with 30 pM of the peptide identified as SEQ ID No: 1; 5 pM of compound CX4945 or 30 pM of Tat peptide, for 24 hours. After the treatment time, the cells were collected, marked with an anti-PDL1 antibody and analyzed by flow cytometry.
- Table 6 shows the percentage of PDL1 positive cells and the mean fluorescence intensity (MFI). Treatment with the peptide identified as SEQ ID No: 1 induced a significant increase in PDL1 expression in both cell lines. This was not observed when cells were treated with CX4945 or Tat peptide.
- Compound CX4945 (at 75 mg/kg body weight) was administered orally in 25 mM NaH 2 PO 4 buffer twice daily. Of the peptide identified as SEQ ID No: 1, 40 mg/kg of weight were administered, and of the anti-PDL1 antibody (clone 10F.9G2, IgG2b kappa rat isotype) 100 pg were administered. Tumor volume and body weight were determined 3 times a week for 40 days. Tumor volume was determined and calculated as described in Example 7. Table 7. Summary of experimental design.
- IP intraperitoneal immunization
- O twice daily oral administration
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3201752A CA3201752A1 (en) | 2020-12-18 | 2021-11-23 | Use of synthetic peptide for the induction of antitumor and antiviral immunty |
JP2023536436A JP2023554401A (ja) | 2020-12-18 | 2021-11-23 | 合成ペプチドの、抗腫瘍及び抗ウイルス免疫の誘導のための使用 |
MX2023007293A MX2023007293A (es) | 2020-12-18 | 2021-11-23 | Uso de peptido sintetico para la induccion de inmunidad antitumoral y antiviral. |
AU2021403339A AU2021403339A1 (en) | 2020-12-18 | 2021-11-23 | Use of synthetic peptide for the induction of antitumor and antiviral immunity |
US18/268,118 US20240082392A1 (en) | 2020-12-18 | 2021-11-23 | Use of synthetic peptide for the induction of antitumor and antiviral immunity |
BR112023011605A BR112023011605A2 (pt) | 2020-12-18 | 2021-11-23 | Uso do peptídeo, método de tratamento de câncer ou infecções virais, e, combinação farmacêutica |
KR1020237023660A KR20230122063A (ko) | 2020-12-18 | 2021-11-23 | 항종양 및 항바이러스 면역 유도를 위한 합성 펩티드의용도 |
CN202180093881.4A CN116963758A (zh) | 2020-12-18 | 2021-11-23 | 用于在诱导抗肿瘤和抗病毒免疫中使用的cigb-300 |
EP21865362.4A EP4265268A2 (en) | 2020-12-18 | 2021-11-23 | Cigb-300 for use in the the induction of antitumor and antiviral immunty |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU2020-0103 | 2020-12-18 | ||
CU2020000103A CU20200103A7 (es) | 2020-12-18 | 2020-12-18 | Péptido sintético para la inducción de inmunidad antitumoral y antiviral |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2022127945A2 true WO2022127945A2 (es) | 2022-06-23 |
WO2022127945A3 WO2022127945A3 (es) | 2022-12-22 |
Family
ID=80683707
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CU2021/050013 WO2022127945A2 (es) | 2020-12-18 | 2021-11-23 | Uso de péptido sintetico para la induccion de inmunidad antitumoral y antiviral |
Country Status (11)
Country | Link |
---|---|
US (1) | US20240082392A1 (es) |
EP (1) | EP4265268A2 (es) |
JP (1) | JP2023554401A (es) |
KR (1) | KR20230122063A (es) |
CN (1) | CN116963758A (es) |
AU (1) | AU2021403339A1 (es) |
BR (1) | BR112023011605A2 (es) |
CA (1) | CA3201752A1 (es) |
CU (1) | CU20200103A7 (es) |
MX (1) | MX2023007293A (es) |
WO (1) | WO2022127945A2 (es) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU23225A1 (es) * | 2001-12-20 | 2007-08-30 | Ct Ingenieria Genetica Biotech | PéPTIDOS PARA EL TRATAMIENTO DEL CáNCER ASOCIADO AL VIRUS PAPILOMA HUMANO (VPH) Y DE OTROS TUMORES EPITELIALES |
CU23511B6 (es) * | 2006-02-28 | 2010-04-13 | Biorec B V | Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas |
-
2020
- 2020-12-18 CU CU2020000103A patent/CU20200103A7/es unknown
-
2021
- 2021-11-23 AU AU2021403339A patent/AU2021403339A1/en active Pending
- 2021-11-23 CN CN202180093881.4A patent/CN116963758A/zh active Pending
- 2021-11-23 CA CA3201752A patent/CA3201752A1/en active Pending
- 2021-11-23 MX MX2023007293A patent/MX2023007293A/es unknown
- 2021-11-23 EP EP21865362.4A patent/EP4265268A2/en active Pending
- 2021-11-23 WO PCT/CU2021/050013 patent/WO2022127945A2/es active Application Filing
- 2021-11-23 US US18/268,118 patent/US20240082392A1/en active Pending
- 2021-11-23 JP JP2023536436A patent/JP2023554401A/ja active Pending
- 2021-11-23 BR BR112023011605A patent/BR112023011605A2/pt unknown
- 2021-11-23 KR KR1020237023660A patent/KR20230122063A/ko unknown
Non-Patent Citations (32)
Title |
---|
BATISTA-ALBUERNE N, J MED ONCOL, vol. 1, 2018, pages 4 |
BENAVENT ACERO F, LUNG CANCER, vol. 107, 2017, pages 14 - 21 |
CHEN HM, CANCER IMMUNOL IMMUNOTHER., vol. 61, 2012, pages 1989 - 2002 |
FARINA HG, EXP CELL RES, vol. 317, 2011, pages 1677 - 1688 |
GRANADILLO M., VACCINE, vol. 37, no. 30, 2019, pages 3957 - 3960 |
HOU W, CELL DEATH AND DISEASE, vol. 4, 2013, pages e966 |
KEEP O, ONCOIMMUNOLOGY, vol. 3, 2014, pages 9 |
KENDERIAN SS, BIOL BLOOD TRANSPLANT, vol. 23, 2017, pages 235 - 246 |
KLENER P JR, CURR PHARM BIOTECHNOL, vol. 16, no. 9, 2015, pages 771 - 781 |
LEE VC, P&T, vol. 42, no. 6, 2017, pages 375 - 383 |
LI X, TUMORI JORNAL, vol. 104, no. 1, 2018, pages 1 - 8 |
LIU X, JORNAL OF HEMATOLOGY & ONCOLOGY, vol. 10, 2017, pages 12 |
MA Y, IMMUNITY, vol. 38, 2013, pages 729 - 41 |
MARTINS LR, ONCOTARGET, vol. 5, 2014, pages 258 - 263 |
MATZINGER P., SCIENCE, vol. 296, 2002, pages 301 - 305 |
MONTICO B, INT J MOL SCÍ., vol. 19, 2018, pages 594 - 609 |
MONTICO B, ONCOIMMUNOLOGY, vol. 6, no. 12, 2017, pages e1356964 |
PEREA SE, CANCER RES, vol. 64, 2004, pages 7129 - 9 |
PEREA SE, CÁNCER RES., vol. 64, 2004, pages 7127 - 7129 |
PERERA Y, MOL CANCER THER, vol. 8, no. 5, 2009 |
ROCK KLKONO H, ANNU REV PATHOL, vol. 3, 2008, pages 99 - 126 |
RUELLA MKENDERIAN SS, BIODRUG, vol. 31, no. 6, 2017, pages 473 - 481 |
SARDUY MR, BRJ CÁNCER, vol. 112, 2015, pages 1636 - 43 |
SOLARES AM, BMC CANCER, vol. 9, no. 1, 2019, pages 146 |
TARTARI F, CANCER TREAT REV, vol. 48, 2016, pages 20 - 24 |
TONG BWANG M, FUTURE ONCOL., vol. 14, no. 21, 2018, pages 2179 - 2188 |
VANDENBERK L, FRONT IMMUNOL, vol. 6, 2016, pages 663 |
VÁZQUEZ-BLOMQUIST D., VIRAL IMMUNOL., vol. 5, no. 2, 2002, pages 337 - 356 |
WEISKOPF K, SCIENCE, vol. 341, no. 6141, 2013, pages 88 - 91 |
YANG Y., J CLÍN INVEST, vol. 125, no. 9, 2015, pages 3335 - 3337 |
ZITVOGEL L, CELL, vol. 140, 2010, pages 798 - 804 |
ZUGAZAGOITIA J, CLÍN THER, vol. 38, no. 7, 2016, pages 1551 - 1566 |
Also Published As
Publication number | Publication date |
---|---|
BR112023011605A2 (pt) | 2023-10-31 |
MX2023007293A (es) | 2023-07-04 |
WO2022127945A3 (es) | 2022-12-22 |
JP2023554401A (ja) | 2023-12-27 |
KR20230122063A (ko) | 2023-08-22 |
EP4265268A2 (en) | 2023-10-25 |
CA3201752A1 (en) | 2022-06-23 |
AU2021403339A1 (en) | 2023-07-06 |
CU20200103A7 (es) | 2022-07-08 |
US20240082392A1 (en) | 2024-03-14 |
CN116963758A (zh) | 2023-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109554353B (zh) | 分离的重组溶瘤痘病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途 | |
ES2460899T3 (es) | Inmunoterapia basada en células cancerosas alógenas | |
JP2008539751A (ja) | 新規組成物およびその使用 | |
JPWO2008096831A1 (ja) | 癌の治療剤 | |
WO2019184459A1 (zh) | 溶瘤病毒疫苗和过继性免疫细胞联合疗法 | |
JP2021176862A (ja) | デングウイルス及び樹状細胞による併用療法のための組成物及び方法 | |
CA2726007A1 (en) | Vaccine compositions with living cell adjuvants and tumor-derived antigens and uses thereof | |
BRPI0817535B1 (pt) | método in vitro eficiente para obter células apresentadoras de antígenos ativadas (apcs), especialmente células dendríticas (dcs), úteis na preparação de vacinas para o tratamento do câncer | |
RU2759728C2 (ru) | Лекарственное средство | |
Öhlschläger et al. | Enhancement of immunogenicity of a therapeutic cervical cancer DNA‐based vaccine by co‐application of sequence‐optimized genetic adjuvants | |
US20120251579A1 (en) | Compositions for generating an antigen specific immune response | |
RU2709015C2 (ru) | Лекарственное средство | |
KR20230165107A (ko) | 백신 아쥬반트로서의 할로겐화 잔텐 | |
Guo et al. | Heterologous prime-boost immunization co-targeting dual antigens inhibit tumor growth and relapse | |
Riezebos-Brilman et al. | Augmentation of alphavirus vector-induced human papilloma virus-specific immune and anti-tumour responses by co-expression of interleukin-12 | |
WO2022127945A2 (es) | Uso de péptido sintetico para la induccion de inmunidad antitumoral y antiviral | |
CN111849905B (zh) | 间充质干细胞靶向运输趋化因子和细胞因子的免疫疗法 | |
JP4780540B2 (ja) | サバイビン由来癌抗原ペプチド | |
RU2379055C1 (ru) | Способ лечения онкологических заболеваний | |
ES2898626T3 (es) | Vacuna terapéutica contra el cáncer a base de proteínas de estrés inmunogénicas | |
US11938182B2 (en) | Halogenated xanthenes as vaccine adjuvants | |
WO2022011651A1 (zh) | 间充质干细胞靶向运输趋化因子和细胞因子的免疫疗法 | |
JP2018070572A (ja) | 免疫治療システム | |
Ratre et al. | Molecular Farming and Anticancer Vaccine: Current Opportunities and Openings | |
JP2017101012A (ja) | 免疫治療製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 3201752 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023536436 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18268118 Country of ref document: US Ref document number: MX/A/2023/007293 Country of ref document: MX |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023011605 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2021403339 Country of ref document: AU Date of ref document: 20211123 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20237023660 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021865362 Country of ref document: EP Effective date: 20230718 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202180093881.4 Country of ref document: CN |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: 112023011605 Country of ref document: BR Free format text: APRESENTAR NOVO CONTEUDO DE LISTAGEM DE SEQUENCIAS CONTENDO TODOS OS CAMPOS OBRIGATORIOS, POIS A LISTAGEM APRESENTADA TEM O CAMPO 130 INDEVIDAMENTE PREENCHIDO. PREENCHER OS CAMPOS 140/141 NA RESPOSTA, UMA VEZ QUE O DEPOSITANTE JA POSSUI O NUMERO DO PEDIDO NO BRASIL. |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21865362 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 112023011605 Country of ref document: BR Kind code of ref document: A2 Effective date: 20230613 |